Shares of Aravive Inc (NASDAQ:ARAV) have earned an average recommendation of “Buy” from the seven analysts that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $26.00.
Several equities research analysts have recently commented on the stock. ValuEngine cut shares of Aravive from a “buy” rating to a “hold” rating in a research report on Thursday, July 2nd. Zacks Investment Research lowered shares of Aravive from a “buy” rating to a “hold” rating in a research note on Tuesday, May 12th. Finally, HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Aravive in a research note on Thursday, April 30th.
Hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC bought a new stake in shares of Aravive in the first quarter worth $32,000. Jane Street Group LLC acquired a new position in Aravive during the first quarter worth $83,000. Wedbush Securities Inc. acquired a new position in Aravive during the first quarter worth $92,000. Invesco Ltd. acquired a new position in Aravive during the first quarter worth $96,000. Finally, Wells Fargo & Company MN increased its holdings in Aravive by 22.3% during the first quarter. Wells Fargo & Company MN now owns 19,843 shares of the company’s stock worth $114,000 after buying an additional 3,616 shares during the last quarter. 41.74% of the stock is currently owned by institutional investors and hedge funds.
Shares of ARAV opened at $11.09 on Tuesday. The firm has a market capitalization of $177.40 million, a price-to-earnings ratio of -5.90 and a beta of 3.52. The company has a debt-to-equity ratio of 0.12, a quick ratio of 12.36 and a current ratio of 12.36. The business’s fifty day moving average price is $12.73 and its two-hundred day moving average price is $10.63. Aravive has a 52 week low of $3.34 and a 52 week high of $15.62.
Aravive (NASDAQ:ARAV) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.36). As a group, research analysts forecast that Aravive will post -1.91 EPS for the current year.
Aravive Company Profile
Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.
Featured Article: How prevalent are 12b-1 fees?
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.